Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3, Multicenter, Randomized, Double-Blind, Comparative Study to Evaluate the Safety and Efficacy of Ceftaroline Versus Vancomycin Plus Aztreonam in Adult Subjects With Complicated Skin and Skin Structure Infection

X
Trial Profile

A Phase 3, Multicenter, Randomized, Double-Blind, Comparative Study to Evaluate the Safety and Efficacy of Ceftaroline Versus Vancomycin Plus Aztreonam in Adult Subjects With Complicated Skin and Skin Structure Infection

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 16 Jun 2020

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ceftaroline fosamil (Primary) ; Aztreonam; Vancomycin
  • Indications Skin and soft tissue infections
  • Focus Registrational; Therapeutic Use
  • Acronyms CANVAS-I; cSSSI
  • Sponsors Cerexa; Forest Laboratories
  • Most Recent Events

    • 21 Apr 2020 Results of exploratory analysis evaluating the impact of underlying comorbidities on clinical outcomes in patients with cSSTI pooled from these three studies presented at the 30th European Congress of Clinical Microbiology and Infectious Diseases
    • 28 Dec 2018 Results assessing safety and tolerability of ceftaroline fosamil q8h and q12h regimens using data from 6 phase three trials (NCT01499277, NCT00424190, NCT00423657, NCT01371838, NCT00621504 and NCT00509106) published in the Journal of Antimicrobial Chemotherapy
    • 24 Apr 2018 Results assessing comparison of safety profile of two regimens of ceftaroline fosamil by using data from six phase III studies (COVERS, CANVAS 1, CANVAS 2, FOCUS 1, FOCUS 2, and asian CAP) presented at the 28th European Congress of Clinical Microbiology and Infectious Diseases.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top